A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases
A Multicenter, Open-label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Dosimetry and Efficacy of BPR-6023021 in Subjects With Advanced Solid Tumors With Bone Metastases.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Rui Dong
- Phone Number: +8613158775185
- Email: rui.dong@btyy.com
Study Contact Backup
- Name: Ruofei Tong
- Phone Number: +86-18002098164
- Email: ruofei.tong@btyy.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University Cancer Center
-
Contact:
- Wei Fan, M.D.
- Phone Number: +86-20-87343415
- Email: fanwei@sysucc.org.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- The age should be up to 18 years at the time of signing the informed consent form (ICF);
- The Eastern Cooperative Oncology Group (ECOG) performance status score should be ≤ 1;
- The expected survival period should be ≥ 3 months
- Phase I and phase II: Subjects with advanced solid tumor bone metastases diagnosed by histology or cytology; and the subjects have failed standard treatment, or have no standard treatment, or are intolerant or not applicable to standard treatment
- Before the first administration, a 99mTc-MDP bone scan diagnosed multiple bone metastases, and at least two site was confirmed by CT or MRI;
- Have adequate organ and bone marrow functions;
- For subjects with reproductive capacity, take effective medical contraceptive measures during the study treatment and within 6 months after the last administration;
- The subjects voluntarily join this study, sign the informed consent form, and can comply with the visit and related procedures stipulated in the protocol.
Exclusion Criteria
- The washout period before the first administration of the study drug was insufficient.
- Previous received similar radionuclide internal irradiation treatment.
- Previous received or planned to receive during the study period semi-body external radiotherapy targeting bone metastases.
- Known "super bone imaging".
- Known spinal cord compression, or clinical imaging manifestations suggesting impending spinal cord compression.
- Any cardiovascular or cerebrovascular diseases or cardiovascular risk factors that may affect the treatment of the study drug.
- Poorly controlled diabetes and hypertension.
- The toxicity of previous anti-tumor treatment before the first administration has not recovered to ≤ 1 grade (evaluated based on NCI-CTCAE v5.0) or has not reached the level specified in the inclusion/exclusion criteria.
- Had other malignant tumors within 5 years before the first administration.
- Subjects with severe and/or uncontrolled concomitant diseases.
- Active hepatitis B or active hepatitis C.
- Human immunodeficiency virus (HIV) test positive or having a history of acquired immune deficiency syndrome (AIDS); known active syphilis infection.
- During the screening process before the first administration, the condition deteriorated rapidly, such as significant changes in the investigator's assessment of physical condition, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Phase 1:Dose escalation
5 dose levels of BPR-6023021 are tentatively planned for Phase 1
|
BPR-6023021 is a Radionuclide conjugated drugs (RDC) targeting bone.
|
|
Experimental: Phase 2: RP2D Cohort
Participants will receive BPR-6023021 for injection at the Recommended Phase 2 Dose (RP2D) determined from the Phase 1 dose escalation study.The dose of BPR-6023021 for injection in Phase 2 is selected based on the Phase 1 monotherapy dose escalation study.
|
BPR-6023021 is a Radionuclide conjugated drugs (RDC) targeting bone.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time Frame: Up to 1 year
|
Up to 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dosimetry,including Maximum plasma concentration (Cmax) of BPR-6023021
Time Frame: Through study completion, an average of 2 year
|
To collect the biological distribution of major tissues/organs and so on.
|
Through study completion, an average of 2 year
|
|
Time to Radiographic Bone Progresion (TTRBP)
Time Frame: Through study completion, an average of 2 year
|
Time from start of treatment to progression of bone lesion (PD) or death, whichever occurs first, during the study period
|
Through study completion, an average of 2 year
|
|
Radiographic progression-free survival (rPFS)
Time Frame: Through study completion, an average of 2 year
|
Time from start of treatment to progression of Disease (PD) or death, whichever occurs first
|
Through study completion, an average of 2 year
|
|
Symptomatic skeletal event-free survival (SSE-FS)
Time Frame: Through study completion, an average of 2 year
|
Time from start of treatment to the first occurrence of new SSE or death from any cause , whichever occurs first.
|
Through study completion, an average of 2 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Yan Yang, Chengdu Syncor Pharmaceutical Co., Ltd.
- Principal Investigator: Wei Fan, Sun Yat-sen University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BPR-6023021-101
- CTR20254494 (Registry Identifier: National Medical Products Administration (NMPA) Drug Clinical Trial Registration And Information Publicity Platform)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.